| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Light Irrevocable Trust #1 dated April 22, 2019 | 6.9% | $16,257,665 | 3,834,355 | Light Irrevocable Trust #1 dated April 22, 2019 | 31 Dec 2024 | |||
| Star Irrevocable Trust #1 dated April 22, 2019 | 6.9% | $16,257,665 | 3,834,355 | Star Irrevocable Trust #1 dated April 22, 2019 | 31 Dec 2024 | |||
| Point72 Asset Management, L.P. | 5.2% | $11,888,585 | 2,942,719 | Point72 Asset Management, L.P. | 27 Aug 2025 | |||
| Logos Global Management LP | 4.4% | -22% | $16,322,350 | -$4,802,600 | 2,515,000 | -23% | Arsani William | 14 Nov 2025 |
As of 30 Sep 2025, 94 institutional investors reported holding 34,492,564 shares of Design Therapeutics, Inc. - Common Stock (DSGN). This represents 60% of the company’s total 57,159,091 outstanding shares.
The largest institutional shareholders of Design Therapeutics, Inc. - Common Stock (DSGN) together control 57% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SR One Capital Management, LP | 11% | 6,526,476 | 0% | 7.1% | $49,144,364 |
| Logos Global Management LP | 6.4% | 3,655,000 | -13% | 2.7% | $27,522,150 |
| Point72 Asset Management, L.P. | 5.8% | 3,340,552 | +85% | 0.05% | $25,154,353 |
| BlackRock, Inc. | 3.6% | 2,044,388 | -15% | 0% | $15,394,241 |
| Frazier Life Sciences Management, L.P. | 3.4% | 1,953,547 | 0% | 0.44% | $14,710,209 |
| TANG CAPITAL MANAGEMENT LLC | 3.1% | 1,780,975 | 0% | 0.52% | $13,410,742 |
| BAKER BROS. ADVISORS LP | 3% | 1,712,882 | 0% | 0.09% | $12,898,001 |
| Almitas Capital LLC | 2.7% | 1,530,435 | 0% | 2.6% | $11,524,176 |
| VANGUARD GROUP INC | 2.5% | 1,443,701 | -1.9% | 0% | $10,871,069 |
| Driehaus Capital Management LLC | 1.9% | 1,076,236 | 0% | 0.06% | $8,104,057 |
| Kynam Capital Management, LP | 1.8% | 1,029,579 | 0% | 0.58% | $7,752,730 |
| FMR LLC | 1.3% | 740,849 | -22% | 0% | $5,578,593 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 695,613 | -12% | 0% | $5,239,165 |
| STATE STREET CORP | 1.1% | 634,397 | -12% | 0% | $4,777,009 |
| ACADIAN ASSET MANAGEMENT LLC | 1.1% | 617,489 | -1.6% | 0.01% | $4,648,000 |
| Woodline Partners LP | 1.1% | 612,712 | -21% | 0.02% | $4,613,721 |
| MPM BIOIMPACT LLC | 0.97% | 555,187 | 0% | 0.68% | $4,180,558 |
| CITADEL ADVISORS LLC | 0.97% | 554,020 | -34% | 0% | $4,171,771 |
| RA CAPITAL MANAGEMENT, L.P. | 0.83% | 475,699 | 0.04% | $3,582,013 | |
| D. E. Shaw & Co., Inc. | 0.65% | 373,276 | -4.4% | 0% | $2,810,768 |
| NORTHERN TRUST CORP | 0.52% | 296,529 | -18% | 0% | $2,232,864 |
| DIMENSIONAL FUND ADVISORS LP | 0.49% | 279,817 | -11% | 0% | $2,105,397 |
| RENAISSANCE TECHNOLOGIES LLC | 0.48% | 274,300 | +2.4% | 0% | $2,065,479 |
| GOLDMAN SACHS GROUP INC | 0.46% | 261,445 | +9.2% | 0% | $1,968,681 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.43% | 247,934 | -1.2% | 0% | $1,866,943 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 82,191 | $770,953 | +$164,592 | $9.38 | 5 |
| 2025 Q3 | 34,492,564 | $259,728,206 | +$644,093 | $7.53 | 94 |
| 2025 Q2 | 34,530,294 | $116,365,282 | +$265,374 | $3.37 | 91 |
| 2025 Q1 | 34,459,430 | $133,014,167 | +$2,133,109 | $3.86 | 95 |
| 2024 Q4 | 33,460,789 | $206,451,772 | +$9,368,489 | $6.17 | 94 |
| 2024 Q3 | 32,032,058 | $172,330,017 | +$1,330,349 | $5.38 | 98 |
| 2024 Q2 | 32,097,220 | $107,523,187 | +$4,413,890 | $3.35 | 92 |
| 2024 Q1 | 30,700,544 | $123,722,605 | -$3,107,582 | $4.03 | 88 |
| 2023 Q4 | 31,717,256 | $84,046,693 | -$1,847,569 | $2.65 | 87 |
| 2023 Q3 | 32,867,255 | $77,567,491 | -$67,849,061 | $2.36 | 84 |
| 2023 Q2 | 38,786,588 | $244,358,163 | +$738,881 | $6.30 | 96 |
| 2023 Q1 | 38,691,853 | $223,252,292 | -$16,074,747 | $5.77 | 94 |
| 2022 Q4 | 40,381,322 | $414,296,202 | -$600,847 | $10.26 | 81 |
| 2022 Q3 | 39,933,593 | $667,698,632 | +$24,544,231 | $16.72 | 76 |
| 2022 Q2 | 38,690,076 | $541,665,132 | +$9,157,438 | $14.00 | 70 |
| 2022 Q1 | 37,990,461 | $613,724,140 | +$27,782,038 | $16.15 | 62 |
| 2021 Q4 | 36,170,094 | $773,127,906 | +$50,180,616 | $21.41 | 58 |
| 2021 Q3 | 28,281,317 | $414,830,000 | +$5,824,856 | $14.69 | 52 |
| 2021 Q2 | 27,817,792 | $545,865,000 | +$37,059,194 | $19.89 | 49 |
| 2021 Q1 | 25,762,953 | $755,185,000 | +$755,158,004 | $29.90 | 43 |